Ken Cacciatore
Stock Analyst at TD Cowen
(0.31)
# 4,215
Out of 4,944 analysts
13
Total ratings
27.27%
Success rate
-28.39%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $15.63 | +219.90% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $7.17 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $14.77 | +35.41% | 4 | May 16, 2023 | |
| SCPH scPharmaceuticals | Initiates: Outperform | $25 | $4.78 | +423.01% | 1 | Dec 1, 2022 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $14.17 | +147.00% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $3.56 | +1,305.48% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $3.26 | +1,433.74% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $14.39 | +212.72% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $14.90 | +2,987.25% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $15.63
Upside: +219.90%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.17
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $14.77
Upside: +35.41%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $4.78
Upside: +423.01%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $14.17
Upside: +147.00%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $3.56
Upside: +1,305.48%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $3.26
Upside: +1,433.74%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $14.39
Upside: +212.72%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $14.90
Upside: +2,987.25%